Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03432520 · ClinicalTrials.gov registry record
Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A
A clinical trial of Hemophilia A, sponsored by Spark Therapeutics.
- Active
- Registry status
- 29
- Enrollment target
- 12
- Study locations
NCT03432520: Active study of Hemophilia A, sponsored by Spark Therapeutics.
NCT03432520 is a study of Hemophilia A that is active but no longer recruiting, run by Spark Therapeutics. The registered enrollment target is 29 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (68% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03432520, a study of Hemophilia A, is active but no longer recruiting, sponsored by Spark Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- 29 participants
- Enrollment target
- 12
- Study locations
Study Summary
This long-term follow-up study will continue to evaluate the long-term safety and efficacy of SPK-8011 and SPK-8016 in males with hemophilia A, who have received a single intravenous administration of SPK-8011 or SPK-8016 in any Spark-sponsored SPK-8011 or SPK-8016 study.
Conditions Studied
Interventions
- GENETIC SPK-8011
- GENETIC SPK-8016
Study Locations (12)
Pennsylvania
- Pennsylvania State University Milton S. Hershey Medical Center - Hershey
- The Children's Hospital of Philadelphia - Philadelphia
- Thomas Jefferson University - Philadelphia
- Hemophilia Center of Western Pennsylvania - Pittsburgh
Massachusetts
- Boston Children's Hospital - Boston
Mississippi
- Mississippi Center for Advanced Medicine - Madison
Missouri
- Truman Medical Centers - Kansas City
Oregon
- Oregon Health & Science University - Portland
Virginia
- Virginia Commonwealth University - Richmond
New South Wales
- Royal Prince Alfred Hospital Department of Cell & Molecular Therapies - Sydney
Victoria
- The Alfred Hospital & Monash Medical Centre - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2032-12 |
What the registry record for NCT03432520 still lists
NCT03432520 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 2 interventions - of which SPK-8011 is the first listed.
NCT03432520 lists 12 locations in 9 states (Pennsylvania, Massachusetts, Mississippi).
Frequently Asked Questions
What is clinical trial NCT03432520 about?
NCT03432520 is a clinical study titled "Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A". This long-term follow-up study will continue to evaluate the long-term safety and efficacy of SPK-8011 and SPK-8016 in males with hemophilia A, who have received a single intravenous administration of SPK-8011 or SPK-8016 in any Spark-sponsored SPK-8011 or SPK-8016 study.
What is the current status of trial NCT03432520?
This trial is currently active not recruiting. The enrollment target is 29 participants. The study started on 2018-08-14. Estimated completion is 2032-12.
What conditions does trial NCT03432520 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT03432520?
The interventions under investigation include: SPK-8011 (GENETIC), SPK-8016 (GENETIC).
Who is sponsoring clinical trial NCT03432520?
This trial is sponsored by Spark Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03432520 being conducted?
This trial has 12 study locations across Massachusetts, Mississippi, Missouri, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03432520's enrollment target sits among peer trials
29 26th of 42 higher than 17 of 42 other Hemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RECRUITING · Phase 4
-
Hemophilia A Research Program
RECRUITING
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI